Comparison of patient baseline characteristics of naproxen, diclofenac, and ibuprofen compared to celecoxib new users in the post- and pre-periods, respectively: logistic regression. Data are OR (95% CI).

	Individual tNSAID vs Celecoxib
	Post-period (2005–07)			Pre-period (2002–04)
	Naproxen	Diclofenac	Ibuprofen	Naproxen	Diclofenac	Ibuprofen
No. patients^*	78,802	49,484	22,257	29,117	16,491	13,578
Age ≥ 65 vs < 65 yrs	0.61 (0.59, 0.63)	0.82 (0.79, 0.84)	0.65 (0.62, 0.68)	0.52 (0.50, 0.54)	0.73 (0.70, 0.77)	0.63 (0.60, 0.67)
Female	0.73 (0.72, 0.75)0	0.79 (0.77, 0.80)	0.67 (0.65, 0.69)	0.61 (0.59, 0.63)	0.65 (0.63, 0.68)	0.63 (0.61, 0.66)
Higher vs lower income	1.10 (1.08, 1.11)	1.15 (1.12, 1.18)	0.99 (0.96, 1.03)	1.01 (0.98, 1.04)	1.16 (1.12, 1.20)	1.03 (0.98, 1.07)
Prescriber specialty
Rheumatologist	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
General practitioner	1.76 (1.58, 1.96)	1.02 (0.92, 1.13)	2.39 (1.93, 2.94)	1.80 (1.51, 2.15)	0.93 (0.80, 1.10)	2.36 (1.76, 3.13)
Internal medicine	2.34 (2.01, 2.73)	1.22 (1.04, 1.43)	2.91 (2.22, 3.81)	2.19 (1.75, 2.74)	0.99 (0.78, 1.25)	2.37 (1.67, 3.35)
Other	2.57 (2.29, 2.88)	1.15 (1.03, 1.28)	5.30 (4.28, 6.56)	2.52 (2.11, 3.02)	1.14 (0.96, 1.35)	4.90 (3.69, 6.52)
Renewal vs first prescription	0.39 (0.36, 0.43)	0.67 (0.62, 0.73)	0.38 (0.33, 0.43)	0.75 (0.68, 0.82)	1.43 (1.31, 1.56)	0.62 (0.54, 0.71)
Rheumatoid arthritis	0.74 (0.65, 0.83)	0.76 (0.67, 0.86)	0.64 (0.52, 0.79)	1.00 (0.82, 1.21)	1.13 (0.92, 1.40)	0.79 (0.59, 1.06)
Osteoarthritis	0.68 (0.65, 0.71)	0.91 (0.88, 0.95)	0.59 (0.55, 0.63)	0.63 (0.59, 0.67)	0.91 (0.85, 0.98)	0.53 (0.48, 0.58)
Gastrointestinal risk level
Low	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Moderate	0.75 (0.72, 0.77)	0.77 (0.74, 0.80)	0.67 (0.64, 0.70)	0.71 (0.68, 0.74)	0.74 (0.70, 0.78)	0.70 (0.66, 0.74)
High	0.49 (0.46, 0.51)	0.56 (0.54, 0.59)	0.47 (0.44, 0.51)	0.41 (0.39, 0.44)	0.52 (0.49, 0.56)	0.45 (0.41, 0.48)
Very high	0.50 (0.43, 0.57)	0.43 (0.36, 0.51)	0.49 (0.39, 0.59)	0.52 (0.42, 0.64)	0.32 (0.23, 0.44)	0.57 (0.44, 0.74)
Cardiovascular risk level
Low	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Moderate	0.87 (0.84, 0.90)	0.94 (0.90, 0.97)	0.75 (0.72, 0.79)	0.88 (0.84, 0.91)	0.90 (0.86, 0.95)	0.79 (0.74, 0.84)
High	0.91 (0.87, 0.95)	0.96 (0.91, 1.01)	0.81 (0.75, 0.86)	0.83 (0.78, 0.88)	0.80 (0.76, 0.85)	0.75 (0.70, 0.81)
Very high	1.30 (1.20, 1.40)	1.06 (0.97, 1.15)	1.02 (0.91, 1.13)	0.98 (0.89, 1.08)	0.88 (0.78, 1.00)	0.83 (0.73, 0.95)
Congestive heart failure risk level
Low	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Moderate	0.94 (0.90, 0.97)	0.99 (0.95, 1.03)	0.71 (0.68, 0.75)	0.94 (0.90, 0.98)	1.02 (0.98, 1.07)	0.70 (0.66, 0.73)
High	0.90 (0.87, 0.94)	0.97 (0.93, 1.02)	0.67 (0.64, 0.71)	0.84 (0.79, 0.89)	0.96 (0.90, 1.03)	0.58 (0.54, 0.62)
Very high	0.90 (0.81, 1.01)	0.99 (0.89, 1.11)	0.68 (0.58, 0.79)	0.86 (0.75, 0.99)	0.96 (0.81, 1.14)	0.52 (0.43, 0.63)
Renal risk level
Low	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
Moderate	1.00 (0.97, 1.04)	0.95 (0.91, 0.98)	2.18 (2.08, 2.29)	0.94 (0.91, 0.98)	0.87 (0.83, 0.92)	2.25 (2.12, 2.37)
High	1.05 (0.94, 1.16)	1.02 (0.91, 1.15)	2.78 (2.41, 3.21)	0.94 (0.81, 1.08)	1.10 (0.94, 1.30)	2.54 (2.12, 3.03)
Very high	1.11 (1.01, 1.22)	0.94 (0.84, 1.05)	2.77 (2.42, 3.16)	1.16 (1.02, 1.32)	0.92 (0.78, 1.09)	2.94 (2.49, 3.47)

↵* New users of celecoxib at index date: post-period 77,051 patients, pre-period 86,425 patients. tNSAID: traditional nonsteroidal antiinflammatory drugs.